HSV-1 triggers paracrine fibroblast growth factor response from cortical brain cells via immediate-early protein ICP0.
Animals
Animals, Newborn
Cerebral Cortex
/ metabolism
Chlorocebus aethiops
Coculture Techniques
Cricetinae
Fibroblast Growth Factors
/ metabolism
Herpesvirus 1, Human
/ metabolism
Humans
Immediate-Early Proteins
/ metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
Mice, Transgenic
Paracrine Communication
/ physiology
Vero Cells
Viral Proteins
/ metabolism
Akt
Cortex
ERK
FGF
Fibroblast growth factors
HSV-1
ICP0
Neurotrophic factors
Signaling
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
02 Dec 2019
02 Dec 2019
Historique:
received:
26
07
2017
accepted:
19
11
2019
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
15
5
2020
Statut:
epublish
Résumé
Herpes simplex virus-1 (HSV-1) infections of the central nervous system (CNS) can result in HSV-1 encephalitis (HSE) which is characterized by severe brain damage and long-term disabilities. Different cell types including neurons and astrocytes become infected in the course of an HSE which leads to an activation of glial cells. Activated glial cells change their neurotrophic factor profile and modulate inflammation and repair. The superfamily of fibroblast growth factors (FGFs) is one of the largest family of neurotrophic factors comprising 22 ligands. FGFs induce pro-survival signaling in neurons and an anti-inflammatory answer in glial cells thereby providing a coordinated tissue response which favors repair over inflammation. Here, we hypothesize that FGF expression is altered in HSV-1-infected CNS cells. We employed primary murine cortical cultures comprising a mixed cell population of astrocytes, neurons, microglia, and oligodendrocytes. Astrocyte reactivity was morphometrically monitored by an automated image analysis algorithm as well as by analyses of A1/A2 marker expression. Altered FGF expression was detected by quantitative real-time PCR and its paracrine FGF activity. In addition, HSV-1 mutants were employed to characterize viral factors important for FGF responses of infected host cells. Astrocytes in HSV-1-infected cortical cultures were transiently activated and became hypertrophic and expressed both A1- and A2-markers. Consistently, a number of FGFs were transiently upregulated inducing paracrine neurotrophic signaling in neighboring cells. Most prominently, FGF-4, FGF-8, FGF-9, and FGF-15 became upregulated in a switch-on like mechanism. This effect was specific for CNS cells and for a fully functional HSV-1. Moreover, the viral protein ICP0 critically mediated the FGF switch-on mechanism. HSV-1 uses the viral protein ICP0 for the induction of FGF-expression in CNS cells. Thus, we propose that HSV-1 triggers FGF activity in the CNS for a modulation of tissue response upon infection.
Sections du résumé
BACKGROUND
BACKGROUND
Herpes simplex virus-1 (HSV-1) infections of the central nervous system (CNS) can result in HSV-1 encephalitis (HSE) which is characterized by severe brain damage and long-term disabilities. Different cell types including neurons and astrocytes become infected in the course of an HSE which leads to an activation of glial cells. Activated glial cells change their neurotrophic factor profile and modulate inflammation and repair. The superfamily of fibroblast growth factors (FGFs) is one of the largest family of neurotrophic factors comprising 22 ligands. FGFs induce pro-survival signaling in neurons and an anti-inflammatory answer in glial cells thereby providing a coordinated tissue response which favors repair over inflammation. Here, we hypothesize that FGF expression is altered in HSV-1-infected CNS cells.
METHOD
METHODS
We employed primary murine cortical cultures comprising a mixed cell population of astrocytes, neurons, microglia, and oligodendrocytes. Astrocyte reactivity was morphometrically monitored by an automated image analysis algorithm as well as by analyses of A1/A2 marker expression. Altered FGF expression was detected by quantitative real-time PCR and its paracrine FGF activity. In addition, HSV-1 mutants were employed to characterize viral factors important for FGF responses of infected host cells.
RESULTS
RESULTS
Astrocytes in HSV-1-infected cortical cultures were transiently activated and became hypertrophic and expressed both A1- and A2-markers. Consistently, a number of FGFs were transiently upregulated inducing paracrine neurotrophic signaling in neighboring cells. Most prominently, FGF-4, FGF-8, FGF-9, and FGF-15 became upregulated in a switch-on like mechanism. This effect was specific for CNS cells and for a fully functional HSV-1. Moreover, the viral protein ICP0 critically mediated the FGF switch-on mechanism.
CONCLUSIONS
CONCLUSIONS
HSV-1 uses the viral protein ICP0 for the induction of FGF-expression in CNS cells. Thus, we propose that HSV-1 triggers FGF activity in the CNS for a modulation of tissue response upon infection.
Identifiants
pubmed: 31791351
doi: 10.1186/s12974-019-1647-5
pii: 10.1186/s12974-019-1647-5
pmc: PMC6889453
doi:
Substances chimiques
Immediate-Early Proteins
0
Viral Proteins
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Références
Trends Genet. 2004 Nov;20(11):563-9
pubmed: 15475116
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Eur Neurol. 2011;65(3):138-43
pubmed: 21358203
Biochem Biophys Res Commun. 2000 Oct 22;277(2):355-60
pubmed: 11032730
Anat Rec (Hoboken). 2019 Aug;302(8):1261-1267
pubmed: 30951263
Exp Neurol. 2016 Jan;275 Pt 3:305-315
pubmed: 25828533
J Virol. 2013 Dec;87(24):13287-96
pubmed: 24089549
Nat Rev Microbiol. 2008 Mar;6(3):211-21
pubmed: 18264117
EMBO J. 1998 Oct 15;17(20):5896-904
pubmed: 9774334
Mol Med Rep. 2015 Oct;12(4):6171-7
pubmed: 26239526
Neuron. 1993 Mar;10(3):369-77
pubmed: 8461132
Nat Protoc. 2012 Sep;7(9):1741-54
pubmed: 22936216
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):E2987-95
pubmed: 25002516
Acta Neuropathol. 2010 Jan;119(1):7-35
pubmed: 20012068
Development. 2014 Aug;141(15):2972-7
pubmed: 25053430
Clin Infect Dis. 2007 Oct 1;45(7):875-80
pubmed: 17806053
PLoS Pathog. 2016 Jun 27;12(6):e1005729
pubmed: 27348812
J Virol. 1996 May;70(5):2842-51
pubmed: 8627758
FASEB J. 2006 Jul;20(9):1484-5
pubmed: 16723380
J Virol. 2014 Nov;88(22):13378-95
pubmed: 25210183
Annu Rev Microbiol. 2013;67:355-74
pubmed: 24024635
Am J Pathol. 1941 Jan;17(1):55-68.1
pubmed: 19970544
Nucleic Acids Res. 1987 Jun 11;15(11):4491-511
pubmed: 3035496
J Virol. 2000 Nov;74(21):9994-10005
pubmed: 11024128
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):E3008-17
pubmed: 23027953
Neuroscience. 2001;104(3):891-9
pubmed: 11440818
Neurochem Int. 2014 Dec;78:35-42
pubmed: 25180676
Inflammopharmacology. 2013 Aug;21(4):309-20
pubmed: 23296919
Biochem Biophys Res Commun. 2010 Sep 24;400(3):389-95
pubmed: 20800574
PLoS One. 2013 May 20;8(5):e64200
pubmed: 23700462
Neural Dev. 2008 Jul 14;3:17
pubmed: 18625063
J Biol Chem. 2000 Mar 17;275(11):8083-90
pubmed: 10713129
J Virol Methods. 2009 Sep;160(1-2):185-8
pubmed: 19414033
Antiviral Res. 2006 Sep;71(2-3):141-8
pubmed: 16675036
J Neurosci. 2012 May 2;32(18):6391-410
pubmed: 22553043
Mol Biol Cell. 2002 Aug;13(8):2795-809
pubmed: 12181347
J Med Virol. 2014 Oct;86(10):1766-71
pubmed: 25042344
Glia. 2014 Aug;62(8):1328-44
pubmed: 24796693
J Virol. 2013 Dec;87(24):13422-32
pubmed: 24089555
Int J Dev Neurosci. 1999 Jun;17(3):191-200
pubmed: 10452363
Glia. 1996 Feb;16(2):93-100
pubmed: 8929896
Front Cell Neurosci. 2018 Aug 08;12:255
pubmed: 30135647
Med Mal Infect. 2017 May;47(3):221-235
pubmed: 28341533
Brain Res. 2001 Sep 7;912(2):105-15
pubmed: 11532426
Brain Res Mol Brain Res. 1996 Sep 5;41(1-2):279-88
pubmed: 8883961
J Neuroimmunol. 2017 Jul 15;308:43-49
pubmed: 28302316
Mol Cell Biol. 2000 Jul;20(13):4922-31
pubmed: 10848617
Mol Syst Biol. 2012 Apr 24;8:579
pubmed: 22531119
Biol Signals Recept. 2001 Sep-Oct;10(5):285-93
pubmed: 11490093
J Virol. 2005 Oct;79(19):12342-54
pubmed: 16160161
J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1334-42
pubmed: 7964808
J Infect Dis. 2002 Oct 15;186 Suppl 1:S3-28
pubmed: 12353183
Dev Dyn. 2008 Jan;237(1):18-27
pubmed: 18058912
Cells. 2014 May 20;3(2):438-54
pubmed: 24852129
Immunity. 1998 Jul;9(1):143-50
pubmed: 9697844
Mayo Clin Proc. 2003 Nov;78(11):1347-52
pubmed: 14601693
J Virol. 2010 Oct;84(20):10802-11
pubmed: 20686034
Trends Neurosci. 1997 Dec;20(12):570-7
pubmed: 9416670
J Virol. 1999 Jul;73(7):5593-604
pubmed: 10364308
Neurology. 2012 Nov 20;79(21):2125-32
pubmed: 23136265
J Neurochem. 2004 Jun;89(5):1092-100
pubmed: 15147501
Science. 1990 Nov 30;250(4985):1262-6
pubmed: 2173860
J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):321-6
pubmed: 9328248
Annu Rev Microbiol. 2012;66:153-76
pubmed: 22726218
Prog Neurobiol. 1999 Feb;57(4):451-84
pubmed: 10080385
Int J Mol Sci. 2015 Dec 28;17(1):
pubmed: 26729092
J Immunol. 2014 Sep 1;193(5):2394-404
pubmed: 25070851
Neurochem Int. 2019 Nov;130:104316
pubmed: 30342960
PLoS One. 2011;6(8):e23564
pubmed: 21876757
Exp Neurol. 1998 Feb;149(2):301-9
pubmed: 9500953
Cell Commun Signal. 2010 Jun 24;8:14
pubmed: 20576134
J Virol. 1989 Nov;63(11):4579-89
pubmed: 2552142
J Virol. 1997 Mar;71(3):2031-40
pubmed: 9032335
Pathogens. 2016 Jun 13;5(2):
pubmed: 27304968
Nat Commun. 2015 May 20;6:7126
pubmed: 25989971
J Virol. 1990 Apr;64(4):1704-15
pubmed: 2157053
J Neuroimmune Pharmacol. 2014 Mar;9(2):102-16
pubmed: 24510686
Int J Mol Sci. 2017 May 18;18(5):
pubmed: 28524074
Genome Biol. 2006;7(10):R100
pubmed: 17076895